Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Net Cash Flow (2016 - 2025)

Iradimed (IRMD) has disclosed Net Cash Flow for 13 consecutive years, with $3.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow rose 10.81% to $3.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.8 million, a 3.43% decrease, with the full-year FY2024 number at $2.5 million, up 130.15% from a year prior.
  • Net Cash Flow was $3.5 million for Q3 2025 at Iradimed, up from $2.7 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $4.4 million in Q2 2021 to a low of -$15.2 million in Q1 2023.
  • A 5-year average of $339864.4 and a median of $2.7 million in 2025 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: soared 430.62% in 2021, then tumbled 1676.35% in 2022.
  • Iradimed's Net Cash Flow stood at $3.6 million in 2021, then tumbled by 34.71% to $2.4 million in 2022, then rose by 27.37% to $3.0 million in 2023, then tumbled by 83.0% to $512856.0 in 2024, then surged by 588.37% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Net Cash Flow are $3.5 million (Q3 2025), $2.7 million (Q2 2025), and -$1.9 million (Q1 2025).